Rose Warren E, Leonard Steven N, Rybak Michael J
Department of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit Receiving Hospital, Detroit, Michigan 48201, USA.
Antimicrob Agents Chemother. 2008 Sep;52(9):3061-7. doi: 10.1128/AAC.00102-08. Epub 2008 Jun 30.
The need to investigate novel dosing regimens and combinations is essential in combating poor treatment outcomes for Staphylococcus aureus bacteremia and endocarditis. We evaluated the impact of simulated standard- and high-dose daptomycin in combination with gentamicin or rifampin against daptomycin-susceptible and nonsusceptible matched strains of S. aureus. These strains were collected from the daptomycin bacteremia and endocarditis clinical trial and consisted of three susceptible strains (MIC, 0.25 mg/liter) and four nonsusceptible isolates (MICs, 2 to 4 mg/liter). Daptomycin regimens of 6 and 10 mg/kg of body weight daily alone and in combination with gentamicin at 5 mg/kg daily or rifampin at 300 mg every 8 h were evaluated using an in vitro model with simulated endocardial vegetations over 96 h. Rapid bactericidal activity, identified by time to 99.9% kill, was displayed in all regimens with the daptomycin-susceptible strains. Concentration-dependent activity was noted by more-rapid killing with the 10-mg/kg/day dose. The addition of gentamicin improved activity in the majority of susceptible isolates. Daptomycin 6-mg/kg/day monotherapy displayed bactericidal activity for only one of the nonsusceptible isolates and for only two isolates with increased doses of 10 mg/kg/day. Combination regimens demonstrated improvement with some but not all nonsusceptible isolates. Three isolates developed a reduction in daptomycin susceptibility with 6-mg/kg/day monotherapy, but this was suppressed with both combination therapy and high-dose daptomycin. These results suggest that high-dose daptomycin therapy and combination therapy may be reasonable treatment options for susceptible isolates; however, more investigations are needed to confirm the variability of these regimens with nonsusceptible isolates.
研究新型给药方案和联合用药对于应对金黄色葡萄球菌菌血症和心内膜炎治疗效果不佳的问题至关重要。我们评估了模拟标准剂量和高剂量达托霉素联合庆大霉素或利福平对达托霉素敏感和不敏感的配对金黄色葡萄球菌菌株的影响。这些菌株取自达托霉素菌血症和心内膜炎的临床试验,包括三株敏感菌株(MIC,0.25毫克/升)和四株不敏感菌株(MIC,2至4毫克/升)。使用体外模拟心内膜赘生物模型,在96小时内评估了每日6毫克/千克和10毫克/千克体重的达托霉素单独用药以及与每日5毫克/千克庆大霉素或每8小时300毫克利福平联合用药的方案。在所有使用达托霉素敏感菌株的方案中,均表现出通过达到99.9%杀灭时间确定的快速杀菌活性。10毫克/千克/天剂量的杀菌速度更快,显示出浓度依赖性活性。添加庆大霉素可提高大多数敏感菌株的活性。每日6毫克/千克的达托霉素单药治疗仅对一株不敏感菌株有杀菌活性,增加至每日10毫克/千克剂量时也仅对两株菌株有杀菌活性。联合用药方案对部分但并非所有不敏感菌株有改善作用。三株菌株在每日6毫克/千克单药治疗时对达托霉素的敏感性降低,但联合治疗和高剂量达托霉素均抑制了这种情况。这些结果表明,高剂量达托霉素治疗和联合治疗可能是敏感菌株的合理治疗选择;然而,需要更多研究来证实这些方案对不敏感菌株的变异性。